Burgeoning research on the human microbiome is facilitating the development of more mechanistically driven probiotics. Charles Schmidt investigates a smattering of probiotic- and microbiota-modifying therapeutic opportunities arising from commercial efforts.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A proposed framework for an appropriate evaluation scheme for microorganisms as novel foods with a health claim in Europe
Microbial Cell Factories Open Access 09 April 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Graessler, J. et al. Pharmacogenomics J. published online, doi:10.1038/tpj.2012.43 (2 October 2012).
van Nood, E. et al. N. Engl. J. Med. 368, 407–415 (2013).
The Human Microbiome Project Consortium. Nature 486, 207–214 (2012).
The Human Microbiome Project Consortium. Nature 486, 215–221 (2012).
Qin, J. et al. Nature 464, 59–65 (2010).
Sokol, H. et al. Proc. Nat. Acad. Sci. USA 105, 16731–16736 (2008).
Turnbaugh, P.J. et al. Nature 444, 1027–1031 (2006).
Cho, I. et al. Nature 488, 621–626 (2012).
Lawley, T.D. et al. PLoS Pathog. 8, e1002995 (2012).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, C. The startup bugs. Nat Biotechnol 31, 279–281 (2013). https://doi.org/10.1038/nbt.2544
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2544
This article is cited by
-
A proposed framework for an appropriate evaluation scheme for microorganisms as novel foods with a health claim in Europe
Microbial Cell Factories (2015)
-
Fecal transplantation poses dilemma for FDA
Nature Biotechnology (2014)